Brain Metastases In ErbB2-Positive Breast Cancer

This study has been terminated.

( Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues. )

Study NCT00437073 Information provided by GlaxoSmithKline

First Received on February 15, 2007. Last Updated on October 25, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Neoplasms, Breast

Additional conditions recognized in this trial

Brain Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Neoplasms

More general conditions related to this trial

Brain Diseases
Breast Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms by Site
Neoplastic Processes
Nervous System Diseases
Nervous System Neoplasms
Pathologic Processes
Skin Diseases

Interventions listed in this trial

capecitabine
topotecan
lapatinib

Additional drug interventions recognized in this trial

Fluorouracil

More general drug interventions related to this trial

Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors

Sponsors listed in this trial

GlaxoSmithKline